{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:18:29Z","timestamp":1783448309723,"version":"3.55.0"},"reference-count":15,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":179,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Functional pituitary tumours, also called pituitary neuroendocrine tumours (PitNETs), typically produce a single hormone, based on the cell lineage from which they arise in the anterior pituitary. Pituitary adenoma dual hypersecretion is less common and may present management dilemmas. Prolactin (PRL) and growth hormone (GH) co-secreting pituitary adenomas (GH and PRL-PA) are the most common form of pituitary adenoma dual hypersecretion, arising from PIT1-lineage PitNETs, most commonly mammosomatotroph and mixed somatotroph\u2013lactotroph adenomas. Pharmacotherapies employed in prolactinoma (i.e. dopamine agonists) and acromegaly (e.g. somatostatin analogues) may be used in GH and PRL-PA, in addition to transsphenoidal surgery. However, the ideal treatment of this rare PA subtype is unknown, reflected by a lack of specific treatment recommendations in both acromegaly and prolactinoma guidelines. Herein, we present an individual with a giant GH and PRL-PA with complete biochemical (GH and PRL), and partial structural, ophthalmological and clinical, responses to upfront cabergoline monotherapy. This case, along with previous data showing GH and structural responses to cabergoline in individuals with acromegaly and hyperprolactinaemia, argue for a role for cabergoline monotherapy in the treatment armamentarium of GH and PRL-PAs, noting that some tumours may exhibit a significant treatment response as observed here.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Learning points<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1530\/eo-25-0077","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T19:21:22Z","timestamp":1767381682000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas"],"prefix":"10.1530","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8127-3045","authenticated-orcid":true,"given":"James M","family":"McNeil","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C","family":"Candy","sequence":"additional","affiliation":[{"name":"3"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair K","family":"Jukes","sequence":"additional","affiliation":[{"name":"1"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-6482","authenticated-orcid":true,"given":"Sunita M C","family":"De Sousa","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026070713571018900_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12020-019-02029-1","article-title":"Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up","volume":"66","author":"Lv","year":"2019","journal-title":"Endocrine"},{"key":"2026070713571018900_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026070713571018900_bib3","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713571018900_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2026070713571018900_bib5","article-title":"Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs","volume":"31","author":"Araujo-Castro","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"2026070713571018900_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/ejendo\/lvae053","article-title":"Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion","volume":"190","author":"Biagetti","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"2026070713571018900_bib7","doi-asserted-by":"crossref","first-page":"e2178","DOI":"10.1210\/clinem\/dgae126","article-title":"Differences between GH- and PRL-cosecreting and GH-Secreting pituitary adenomas: a series of 604 cases","volume":"109","author":"Araujo-Castro","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713571018900_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11102-025-01556-7","article-title":"Dopamine receptor expression predicts cabergoline response in persistent somatotroph adenoma","volume":"28","author":"Rajan","year":"2025","journal-title":"Pituitary"},{"key":"2026070713571018900_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1210\/jcem-64-2-391","article-title":"Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen","volume":"64","author":"Prior","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713571018900_bib10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cen.13940","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British society of echocardiography, the British heart valve society and the society for endocrinology","volume":"90","author":"Steeds","year":"2019","journal-title":"Clin Endocrinol"},{"key":"2026070713571018900_bib11","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EO-21-0038","article-title":"Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?","volume":"2","author":"De Sousa","year":"2022","journal-title":"Endocr Oncol"},{"key":"2026070713571018900_bib12","article-title":"Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma","volume":"3","author":"Hayes","year":"2023","journal-title":"Endocr Oncol"},{"key":"2026070713571018900_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/ejendo\/lvae003","article-title":"Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study","volume":"190","author":"Urwyler","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"2026070713571018900_bib14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4158\/EP.13.4.396","article-title":"Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy","volume":"13","author":"Vilar","year":"2007","journal-title":"Endocr Pract"},{"key":"2026070713571018900_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/B:PITU.0000044630.83354.f0","article-title":"Cabergoline therapy of growth hormone & growth hormone\/prolactin secreting pituitary tumors","volume":"7","author":"Freda","year":"2004","journal-title":"Pituitary"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/6\/1\/EO-25-0077.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/6\/1\/EO-25-0077.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0077\/505834\/eo-25-0077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-25-0077\/505834\/eo-25-0077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:58:02Z","timestamp":1783447082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e250077\/75464\/Cabergoline-monotherapy-in-GH-and-PRL-cosecreting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-25-0077","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"e250077"}}